Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease

Summary

Late stage lower extremity arterial disease (LEAD) is known to be associated with hemodynamic and metabolic abnormalities and very poor long-term prognosis. The prognostic value of hemodynamic and metabolic profiling, however, is yet to be determined in this patient group.

Current study aims to identify novel prognostic biomarkers for better risk stratification of late stage LEAD patients. It also allows to determine associations between hemodynamic/arterial stiffness indices, low-molecular weight metabolites and other substances (e.g. mediators of inflammation and bone-mineral metabolism, cardiac and kidney injury biomarkers, microRNAs) thus providing potentially valuable insight into the pathogenic mechanisms of this disease.

Conditions

• Lower Extremity Arterial Disease (Fontaine Stages IIb-IV)

Sponsors & Collaborators

• Estonian Science Foundation

  collaborator OTHER_GOV

• Tartu University Hospital

  collaborator OTHER

• University of Tartu

  lead OTHER

Principal Investigators

• Jaak Kals, MD, PhD · University of Tartu

• Jaan Eha, MD, PhD · University of Tartu

• Mihkel Zilmer, dr. med. · University of Tartu

• Kaido Paapstel, MD, PhD · University of Tartu

• Kaspar Tootsi, MD, PhD · University of Tartu

• Karl Kuusik, MD · University of Tartu

• Tuljo Ööbik, MD · University of Tartu

• Riina Kaur · University of Tartu

Eligibility

Min Age

35 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-11-04

Primary Completion

2024-12-31

Completion

2025-12-31

Countries

• Estonia

Study Locations